The U.S. Court of Appeals Denies Rehearing on Cuts to 340B Drug Pricing Program
By EsqSocial Corporation 03/11/20
In a setback to hospitals challenging deep cuts to reimbursement for prescription drugs acquired through the 340B drug pricing program (“340B Program”), the U.S. Court of Appeals for the District of Columbia, on October 19, denied a request to reconsider a decision by three-judge panels of the Court upholding these cuts. Short of a Supreme Court appeal, this decision effectively ends hospital challenges to these reimbursement reductions, and makes the implementation of additional cuts in 2021 a...
By: Sheppard Mullin Richter & Hampton LLP